Supplementary Figures S1-S8 from Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors

Francica, Brian J.; Holtz, Anja; Lopez, Justine; Freund, David; Chen, Austin; Wang, Dingzhi; Powell, David; Kipper, Franciele; Panigrahy, Dipak; Dubois, Raymond N.; Whiting, Chan C.; Prasit, Peppi; Dubensky, Thomas W.

doi:10.1158/2767-9764.23905684.v1

Supplementary Figures S1-S8 from Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors

journal contribution

posted on 2023-08-08, 14:20 authored by Brian J. Francica, Anja Holtz, Justine Lopez, David Freund, Austin Chen, Dingzhi Wang, David Powell, Franciele Kipper, Dipak Panigrahy, Raymond N. Dubois, Chan C. Whiting, Peppi Prasit, Thomas W. Dubensky

Supplementary Figures S1-S8

Funding

Tempest Therapeutics

History

ARTICLE ABSTRACT

Prostaglandin (PGE2) drives tumor progression but the pathway has not been effectively drugged. We demonstrate significantly enhanced immunologic potency and antitumor activity through blockade of EP2 and EP4 PGE2 receptor signaling together with a single molecule.